Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says Heather Wenberg, BSN, RN, OCN.
Heather Wenberg, BSN, RN, OCN
Advertisement
Heather Wenberg, BSN, RN, OCN, is the regional director of nursing at American Oncology Network.
Articles by Heather Wenberg, BSN, RN, OCN
The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
